{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:27:18Z","timestamp":1772105238873,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The transmission of resistant HIV variants jeopardizes the effective use of antiretrovirals for therapy and prophylaxis. Molecular surveillance of new HIV diagnoses with a focus on prevalence and type of resistance associated mutations and the subtype of circulating viruses is mandatory.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>From 2017 to 2020, 11,527 new HIV diagnoses were reported in Germany to the Robert Koch Institute (RKI). Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and integrase (IN) sequences were obtained from 3097 (26.9%) cases. The sequences were analyzed with data from the national HIV reports.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among all cases in the analysis, the proportion of primary resistance was 4.3% for nucleoside reverse-transcriptase inhibitors (NRTIs), 9.2% for non-NRTI (NNRTIs), 3.3% for protease inhibitors (PIs) and 1.4% for integrase inhibitors (INIs). Dual-class resistance was highest for NRTIs\/NNRTIs with 1.2%. There was no trend in the proportion of viruses resistant to drug classes. Most individual key mutations associated with relevant resistance had a prevalence below 1% including K65R (0.1%) and M184V (0.6%). A notable exception was K103NS, with a prevalence of 2.9% and a significant increase (p<jats:sub>Trend<\/jats:sub>=0.024) during 2017\u20132020. In this period, diagnoses of infections with HIV-1 subtype B were the most common at 58.7%, but its prevalence was declining (p<jats:sub>Trend<\/jats:sub>=0.049) while the frequency of minority subtypes (each &lt;\u20091%) increased (p<jats:sub>Trend<\/jats:sub>=0.007). Subtype B was highest (75.6%) in men who have sex with men (MSM) and lowest in reported heterosexual transmissions (HETs, 22.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The percentage of primary resistance was high but at a stable level. A genotypic determination of resistance is therefore still required before the start of therapy. The subtype diversity of circulating HIV-1 is increasing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08649-3","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T09:02:48Z","timestamp":1696928568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017\u20132020"],"prefix":"10.1186","volume":"23","author":[{"given":"Uwe","family":"Fiebig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Koppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gunsenheimer-Bartmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Baumgarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"issue":"10189","key":"8649_CR1","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428\u201338.","journal-title":"Lancet"},{"key":"8649_CR2","first-page":"3","volume":"47","author":"MMU An der Heiden","year":"2021","unstructured":"An der Heiden MMU, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer BBV. Sch\u00e4tzung der Zahl der HIV-Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland, stand Ende 2020. Epid Bull. 2021;47:3\u201317.","journal-title":"Epid Bull"},{"issue":"5","key":"8649_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/cid\/civ963","volume":"62","author":"LM Hofstra","year":"2016","unstructured":"Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver D, Asjo B, Beshkov D, Coughlan S, et al. Transmission of HIV Drug Resistance and the predicted effect on current first-line Regimens in Europe. Clin Infect Dis. 2016;62(5):655\u201363.","journal-title":"Clin Infect Dis"},{"key":"8649_CR4","unstructured":"Deutsch-\u00d6sterreichische. Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion, AWMF 055 \u2013 001, Version 8 vom 01.09.2020."},{"key":"8649_CR5","unstructured":"European AIDS Clinical Society (EACS). Guidelines version 11.0, October 2021."},{"key":"8649_CR6","doi-asserted-by":"crossref","unstructured":"van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML et al. Piloting a surveillance system for HIV drug resistance in the European Union. Euro Surveill 2019, 24(19).","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800390"},{"key":"8649_CR7","doi-asserted-by":"crossref","unstructured":"Marcus U, Schmidt D, Schink SB, Koppe U. Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. Z Gesundh Wiss 2022:1\u201317.","DOI":"10.21203\/rs.3.rs-156075\/v3"},{"key":"8649_CR8","unstructured":"HIV drug resistance report 2021. Geneva: World Health Organization; 2021."},{"issue":"7","key":"8649_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/cid\/ciz372","volume":"70","author":"EP Hyle","year":"2020","unstructured":"Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP. Clinical impact and cost-effectiveness of genotype testing at Human Immunodeficiency Virus diagnosis in the United States. Clin Infect Dis. 2020;70(7):1353\u201363.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"8649_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cid\/cix542","volume":"65","author":"Y Koullias","year":"2017","unstructured":"Koullias Y, Sax PE, Fields NF, Walensky RP, Hyle EP. Should we be testing for baseline integrase resistance in patients newly diagnosed with Human Immunodeficiency Virus? Clin Infect Dis. 2017;65(8):1274\u201381.","journal-title":"Clin Infect Dis"},{"key":"8649_CR11","doi-asserted-by":"crossref","unstructured":"Hanke K, Faria NR, Kuhnert D, Yousef KP, Hauser A, Meixenberger K, Hofmann A, Bremer V, Bartmeyer B, Pybus O et al. Reconstruction of the genetic history and the current spread of HIV-1 subtype A in Germany. J Virol 2019, 93(12).","DOI":"10.1128\/JVI.02238-18"},{"key":"8649_CR12","doi-asserted-by":"crossref","unstructured":"Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, Bannert N. National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill 2017, 22(2).","DOI":"10.2807\/1560-7917.ES.2017.22.2.30436"},{"issue":"16","key":"8649_CR13","doi-asserted-by":"publisher","first-page":"W13","DOI":"10.1097\/01.aids.0000247564.73009.bc","volume":"20","author":"J Hemelaar","year":"2006","unstructured":"Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20(16):W13\u201323.","journal-title":"AIDS"},{"key":"8649_CR14","first-page":"3","volume":"31","author":"U Marcus","year":"2021","unstructured":"Marcus U, Kollan C, Gunsenheimer-Bartmeyer B, Bremer V. HIV-Jahresbericht 2019\/2020. Epid Bul. 2021;31:3\u201315.","journal-title":"Epid Bul"},{"issue":"11","key":"8649_CR15","doi-asserted-by":"publisher","first-page":"e0206234","DOI":"10.1371\/journal.pone.0206234","volume":"13","author":"A Hauser","year":"2018","unstructured":"Hauser A, Hofmann A, Meixenberger K, Altmann B, Hanke K, Bremer V, Bartmeyer B, Bannert N. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: results from the national molecular surveillance of new HIV-diagnoses. PLoS ONE. 2018;13(11):e0206234.","journal-title":"PLoS ONE"},{"issue":"27\u201328","key":"8649_CR16","first-page":"479","volume":"120","author":"U Fiebig","year":"2023","unstructured":"Fiebig U, Altmann B, Hauser A, Koppe U, Hanke K, Gunsenheimer-Bartmeyer B, Bremer V, Baumgarten A, Bannert N. Primary resistance of viruses in reported new cases of HIV, 2017\u20132020. Dtsch Arztebl Int. 2023;120(27\u201328):479\u201380.","journal-title":"Dtsch Arztebl Int"},{"key":"8649_CR17","unstructured":"Robert Koch Institute [https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Studien\/InzSurv_HIV\/beteilte_Labore.html. Accessed 04 April 2023]."},{"issue":"11","key":"8649_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608\u201318.","journal-title":"Clin Infect Dis"},{"key":"8649_CR19","unstructured":"Stanford, HIVdb. [https:\/\/hivdb.stanford.edu\/. Accessed 04 May 2021]."},{"key":"8649_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","volume":"19","author":"AC Pineda-Pena","year":"2013","unstructured":"Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, Gomez-Lopez A, Camacho RJ, de Oliveira T, Vandamme AM. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337\u201348.","journal-title":"Infect Genet Evol"},{"issue":"18","key":"8649_CR21","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/nar\/gku739","volume":"42","author":"D Struck","year":"2014","unstructured":"Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18):e144.","journal-title":"Nucleic Acids Res"},{"key":"8649_CR22","doi-asserted-by":"publisher","first-page":"180148","DOI":"10.1038\/sdata.2018.148","volume":"5","author":"SY Rhee","year":"2018","unstructured":"Rhee SY, Shafer RW. Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences. Sci Data. 2018;5:180148.","journal-title":"Sci Data"},{"key":"8649_CR23","first-page":"493","volume":"46","author":"U Marcus","year":"2019","unstructured":"Marcus UG-BB, Kollan C, Bremer V. HIV Jahresbericht 2017\/2018. Epid Bull. 2019;46:493\u2013501.","journal-title":"Epid Bull"},{"key":"8649_CR24","volume-title":"On HIV drug resistance 2017\u20132021","author":"Global action plan","year":"2017","unstructured":"Global action plan. On HIV drug resistance 2017\u20132021. Geneva: World Health Organization; 2017."},{"key":"8649_CR25","volume-title":"Strategy, 2021 update","author":"HIV drug resistance","year":"2021","unstructured":"HIV drug resistance. Strategy, 2021 update. Geneva: World Health Organization; 2021."},{"key":"8649_CR26","volume-title":"Surveillance in countries scaling up pre-exposure prophylaxis","author":"HIV drug resistance","year":"2020","unstructured":"HIV drug resistance. Surveillance in countries scaling up pre-exposure prophylaxis. Geneva: World Health Organization; 2020."},{"key":"8649_CR27","unstructured":"Consolidated. Guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021."},{"issue":"6","key":"8649_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","volume":"74","author":"RP McClung","year":"2022","unstructured":"McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, Hernandez AL. Transmitted Drug Resistance among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014\u20132018. Clin Infect Dis. 2022;74(6):1055\u201362.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"8649_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"8649_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12913-021-07390-4","volume":"22","author":"M Lottes","year":"2022","unstructured":"Lottes M, Bremer V, Prugger C, Kollan C, Schmidt D. Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019. BMC Health Serv Res. 2022;22(1):63.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"8649_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/infdis\/jit345","volume":"208","author":"H Castro","year":"2013","unstructured":"Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT. Resistance UKCGoHD: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208(9):1459\u201363.","journal-title":"J Infect Dis"},{"issue":"14","key":"8649_CR32","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1128\/JVI.02747-05","volume":"80","author":"Z Hu","year":"2006","unstructured":"Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol. 2006;80(14):7020\u20137.","journal-title":"J Virol"},{"issue":"3","key":"8649_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/COH.0000000000000534","volume":"14","author":"N Bbosa","year":"2019","unstructured":"Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14(3):153\u201360.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5\u20136","key":"8649_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000477811","volume":"59","author":"J Neubert","year":"2016","unstructured":"Neubert J, Michalsky N, Laws HJ, Borkhardt A, Jensen B, Lubke N. HIV-1 subtype diversity and prevalence of primary drug resistance in a Single-Center Pediatric Cohort in Germany. Intervirology. 2016;59(5\u20136):301\u20136.","journal-title":"Intervirology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08649-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08649-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08649-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T22:06:06Z","timestamp":1700258766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08649-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8649"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08649-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VB received travel expense support from the organizers of the German-Austrian AIDS Congress. She is a member of DAIG and the coordinating committee of the Federal government to implement the strategy to contain HIV, hepatitis B and C and other sexually transmitted infections. UK received travel expense support from the organizers of the German-Austrian AIDS Congress and is a member of DAIG. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The RKI is the German national public health institute. It receives and analyses notifications on new HIV infections and performs molecular surveillance according to the Protection Against Infections Act (IfSG). We report data from a national molecular surveillance program of new HIV diagnoses performed according to the German law (Protection Against Infections Act \u00a7\u00a013). An ethics statement or consent for participation is not needed. All methods were carried out in accordance with relevant guidelines and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"673"}}